CRISPR-Cas9 used to prevent Fuchs’ corneal dystrophy in mice
Scientists have shown that start codon disruption with CRISPR-Cas9 gene editing can prevent Fuchs’ corneal dystrophy in mouse models.
List view / Grid view
Scientists have shown that start codon disruption with CRISPR-Cas9 gene editing can prevent Fuchs’ corneal dystrophy in mouse models.
New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Listen to this podcast to discover how SARS-CoV-2 variants are sequenced and why PCR assays could provide an alternative for resource-constrained places.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.